nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinolone Acetonide—PLA2G4A—Epirubicin—pancreatic cancer	0.726	1	CbGbCtD
Fluocinolone Acetonide—Cough—Erlotinib—pancreatic cancer	0.000555	0.00257	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Sunitinib—pancreatic cancer	0.000554	0.00256	CcSEcCtD
Fluocinolone Acetonide—Erythema—Sunitinib—pancreatic cancer	0.00055	0.00254	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Sunitinib—pancreatic cancer	0.00055	0.00254	CcSEcCtD
Fluocinolone Acetonide—Visual disturbance—Docetaxel—pancreatic cancer	0.000549	0.00254	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Tamoxifen—pancreatic cancer	0.000547	0.00253	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Erlotinib—pancreatic cancer	0.000541	0.0025	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Sunitinib—pancreatic cancer	0.000539	0.00249	CcSEcCtD
Fluocinolone Acetonide—Viral infection—Epirubicin—pancreatic cancer	0.000535	0.00248	CcSEcCtD
Fluocinolone Acetonide—Back pain—Sunitinib—pancreatic cancer	0.000532	0.00246	CcSEcCtD
Fluocinolone Acetonide—Lacrimation increased—Epirubicin—pancreatic cancer	0.000525	0.00243	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Epirubicin—pancreatic cancer	0.000525	0.00243	CcSEcCtD
Fluocinolone Acetonide—Oedema—Tamoxifen—pancreatic cancer	0.000524	0.00243	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Irinotecan—pancreatic cancer	0.000522	0.00241	CcSEcCtD
Fluocinolone Acetonide—Sinusitis—Fluorouracil—pancreatic cancer	0.000521	0.00241	CcSEcCtD
Fluocinolone Acetonide—Infection—Tamoxifen—pancreatic cancer	0.000521	0.00241	CcSEcCtD
Fluocinolone Acetonide—Pain in extremity—Docetaxel—pancreatic cancer	0.00052	0.00241	CcSEcCtD
Fluocinolone Acetonide—Oedema—Erlotinib—pancreatic cancer	0.000519	0.0024	CcSEcCtD
Fluocinolone Acetonide—Infection—Erlotinib—pancreatic cancer	0.000515	0.00238	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Irinotecan—pancreatic cancer	0.000512	0.00237	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Erlotinib—pancreatic cancer	0.000509	0.00235	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Gemcitabine—pancreatic cancer	0.000509	0.00235	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Irinotecan—pancreatic cancer	0.000502	0.00232	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Fluorouracil—pancreatic cancer	0.0005	0.00231	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Gemcitabine—pancreatic cancer	0.000498	0.00231	CcSEcCtD
Fluocinolone Acetonide—Viral infection—Doxorubicin—pancreatic cancer	0.000495	0.00229	CcSEcCtD
Fluocinolone Acetonide—Neck pain—Epirubicin—pancreatic cancer	0.000489	0.00226	CcSEcCtD
Fluocinolone Acetonide—Lacrimation increased—Doxorubicin—pancreatic cancer	0.000485	0.00224	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Doxorubicin—pancreatic cancer	0.000485	0.00224	CcSEcCtD
Fluocinolone Acetonide—Cough—Sunitinib—pancreatic cancer	0.00048	0.00222	CcSEcCtD
Fluocinolone Acetonide—Dermatitis contact—Epirubicin—pancreatic cancer	0.000478	0.00221	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Tamoxifen—pancreatic cancer	0.000478	0.00221	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Erlotinib—pancreatic cancer	0.000473	0.00219	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Irinotecan—pancreatic cancer	0.000469	0.00217	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Sunitinib—pancreatic cancer	0.000469	0.00217	CcSEcCtD
Fluocinolone Acetonide—Nasopharyngitis—Docetaxel—pancreatic cancer	0.000465	0.00215	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Irinotecan—pancreatic cancer	0.00046	0.00213	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Gemcitabine—pancreatic cancer	0.000457	0.00211	CcSEcCtD
Fluocinolone Acetonide—Neck pain—Doxorubicin—pancreatic cancer	0.000453	0.00209	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.000453	0.00209	CcSEcCtD
Fluocinolone Acetonide—Oedema—Sunitinib—pancreatic cancer	0.000449	0.00208	CcSEcCtD
Fluocinolone Acetonide—Pain—Tamoxifen—pancreatic cancer	0.000448	0.00207	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Gemcitabine—pancreatic cancer	0.000448	0.00207	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.000448	0.00207	CcSEcCtD
Fluocinolone Acetonide—Dry eye—Epirubicin—pancreatic cancer	0.000447	0.00207	CcSEcCtD
Fluocinolone Acetonide—Infection—Sunitinib—pancreatic cancer	0.000446	0.00206	CcSEcCtD
Fluocinolone Acetonide—Pain—Erlotinib—pancreatic cancer	0.000444	0.00205	CcSEcCtD
Fluocinolone Acetonide—Dermatitis contact—Doxorubicin—pancreatic cancer	0.000442	0.00204	CcSEcCtD
Fluocinolone Acetonide—Erythema—Gemcitabine—pancreatic cancer	0.000442	0.00204	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Fluorouracil—pancreatic cancer	0.000441	0.00204	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Sunitinib—pancreatic cancer	0.00044	0.00204	CcSEcCtD
Fluocinolone Acetonide—Back pain—Irinotecan—pancreatic cancer	0.000438	0.00203	CcSEcCtD
Fluocinolone Acetonide—Erythema—Fluorouracil—pancreatic cancer	0.000434	0.00201	CcSEcCtD
Fluocinolone Acetonide—Back pain—Gemcitabine—pancreatic cancer	0.000427	0.00198	CcSEcCtD
Fluocinolone Acetonide—Dry eye—Doxorubicin—pancreatic cancer	0.000413	0.00191	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Erlotinib—pancreatic cancer	0.00041	0.0019	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.000409	0.00189	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Fluorouracil—pancreatic cancer	0.000409	0.00189	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Irinotecan—pancreatic cancer	0.000407	0.00188	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Docetaxel—pancreatic cancer	0.000401	0.00185	CcSEcCtD
Fluocinolone Acetonide—Infestation—Docetaxel—pancreatic cancer	0.000401	0.00185	CcSEcCtD
Fluocinolone Acetonide—Cough—Irinotecan—pancreatic cancer	0.000396	0.00183	CcSEcCtD
Fluocinolone Acetonide—Eczema—Epirubicin—pancreatic cancer	0.000391	0.00181	CcSEcCtD
Fluocinolone Acetonide—Eye pain—Epirubicin—pancreatic cancer	0.000389	0.0018	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000388	0.00179	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Tamoxifen—pancreatic cancer	0.000386	0.00179	CcSEcCtD
Fluocinolone Acetonide—Cough—Gemcitabine—pancreatic cancer	0.000385	0.00178	CcSEcCtD
Fluocinolone Acetonide—Pain—Sunitinib—pancreatic cancer	0.000384	0.00178	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Gemcitabine—pancreatic cancer	0.000376	0.00174	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Tamoxifen—pancreatic cancer	0.000371	0.00172	CcSEcCtD
Fluocinolone Acetonide—Oedema—Irinotecan—pancreatic cancer	0.00037	0.00171	CcSEcCtD
Fluocinolone Acetonide—Infection—Irinotecan—pancreatic cancer	0.000368	0.0017	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Erlotinib—pancreatic cancer	0.000367	0.0017	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Irinotecan—pancreatic cancer	0.000363	0.00168	CcSEcCtD
Fluocinolone Acetonide—Eczema—Doxorubicin—pancreatic cancer	0.000361	0.00167	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Docetaxel—pancreatic cancer	0.000361	0.00167	CcSEcCtD
Fluocinolone Acetonide—Oedema—Gemcitabine—pancreatic cancer	0.00036	0.00167	CcSEcCtD
Fluocinolone Acetonide—Eye pain—Doxorubicin—pancreatic cancer	0.00036	0.00166	CcSEcCtD
Fluocinolone Acetonide—Hypoglycaemia—Epirubicin—pancreatic cancer	0.00036	0.00166	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Tamoxifen—pancreatic cancer	0.000359	0.00166	CcSEcCtD
Fluocinolone Acetonide—Infection—Gemcitabine—pancreatic cancer	0.000358	0.00166	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Sunitinib—pancreatic cancer	0.000355	0.00164	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Erlotinib—pancreatic cancer	0.000355	0.00164	CcSEcCtD
Fluocinolone Acetonide—Oedema—Fluorouracil—pancreatic cancer	0.000354	0.00164	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Docetaxel—pancreatic cancer	0.000354	0.00164	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000353	0.00163	CcSEcCtD
Fluocinolone Acetonide—Infection—Fluorouracil—pancreatic cancer	0.000352	0.00163	CcSEcCtD
Fluocinolone Acetonide—Pain in extremity—Epirubicin—pancreatic cancer	0.000351	0.00162	CcSEcCtD
Fluocinolone Acetonide—Diplopia—Epirubicin—pancreatic cancer	0.000351	0.00162	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000347	0.00161	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Docetaxel—pancreatic cancer	0.000347	0.0016	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Tamoxifen—pancreatic cancer	0.000347	0.0016	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Erlotinib—pancreatic cancer	0.000343	0.00159	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Docetaxel—pancreatic cancer	0.000336	0.00156	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Tamoxifen—pancreatic cancer	0.000333	0.00154	CcSEcCtD
Fluocinolone Acetonide—Hypoglycaemia—Doxorubicin—pancreatic cancer	0.000333	0.00154	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Sunitinib—pancreatic cancer	0.000331	0.00153	CcSEcCtD
Fluocinolone Acetonide—Rash—Tamoxifen—pancreatic cancer	0.000331	0.00153	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Tamoxifen—pancreatic cancer	0.00033	0.00153	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Erlotinib—pancreatic cancer	0.00033	0.00153	CcSEcCtD
Fluocinolone Acetonide—Headache—Tamoxifen—pancreatic cancer	0.000329	0.00152	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000328	0.00152	CcSEcCtD
Fluocinolone Acetonide—Rash—Erlotinib—pancreatic cancer	0.000327	0.00151	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Erlotinib—pancreatic cancer	0.000327	0.00151	CcSEcCtD
Fluocinolone Acetonide—Headache—Erlotinib—pancreatic cancer	0.000325	0.0015	CcSEcCtD
Fluocinolone Acetonide—Pain in extremity—Doxorubicin—pancreatic cancer	0.000325	0.0015	CcSEcCtD
Fluocinolone Acetonide—Diplopia—Doxorubicin—pancreatic cancer	0.000325	0.0015	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Docetaxel—pancreatic cancer	0.000324	0.0015	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000323	0.00149	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000319	0.00148	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Docetaxel—pancreatic cancer	0.000318	0.00147	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Sunitinib—pancreatic cancer	0.000318	0.00147	CcSEcCtD
Fluocinolone Acetonide—Pain—Irinotecan—pancreatic cancer	0.000316	0.00146	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Docetaxel—pancreatic cancer	0.000315	0.00146	CcSEcCtD
Fluocinolone Acetonide—Nasopharyngitis—Epirubicin—pancreatic cancer	0.000314	0.00145	CcSEcCtD
Fluocinolone Acetonide—Erythema—Docetaxel—pancreatic cancer	0.000313	0.00145	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Docetaxel—pancreatic cancer	0.000313	0.00145	CcSEcCtD
Fluocinolone Acetonide—Nausea—Tamoxifen—pancreatic cancer	0.000311	0.00144	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000311	0.00144	CcSEcCtD
Fluocinolone Acetonide—Pain—Gemcitabine—pancreatic cancer	0.000308	0.00143	CcSEcCtD
Fluocinolone Acetonide—Nausea—Erlotinib—pancreatic cancer	0.000308	0.00143	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Sunitinib—pancreatic cancer	0.000307	0.00142	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Docetaxel—pancreatic cancer	0.000307	0.00142	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000306	0.00141	CcSEcCtD
Fluocinolone Acetonide—Influenza—Epirubicin—pancreatic cancer	0.000303	0.0014	CcSEcCtD
Fluocinolone Acetonide—Back pain—Docetaxel—pancreatic cancer	0.000303	0.0014	CcSEcCtD
Fluocinolone Acetonide—Pain—Fluorouracil—pancreatic cancer	0.000303	0.0014	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Sunitinib—pancreatic cancer	0.000297	0.00137	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Irinotecan—pancreatic cancer	0.000292	0.00135	CcSEcCtD
Fluocinolone Acetonide—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.00029	0.00134	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Sunitinib—pancreatic cancer	0.000286	0.00132	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Gemcitabine—pancreatic cancer	0.000285	0.00132	CcSEcCtD
Fluocinolone Acetonide—Rash—Sunitinib—pancreatic cancer	0.000283	0.00131	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Sunitinib—pancreatic cancer	0.000283	0.00131	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000282	0.0013	CcSEcCtD
Fluocinolone Acetonide—Headache—Sunitinib—pancreatic cancer	0.000281	0.0013	CcSEcCtD
Fluocinolone Acetonide—Influenza—Doxorubicin—pancreatic cancer	0.000281	0.0013	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Fluorouracil—pancreatic cancer	0.00028	0.0013	CcSEcCtD
Fluocinolone Acetonide—Cough—Docetaxel—pancreatic cancer	0.000273	0.00126	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Irinotecan—pancreatic cancer	0.000273	0.00126	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Epirubicin—pancreatic cancer	0.00027	0.00125	CcSEcCtD
Fluocinolone Acetonide—Infestation—Epirubicin—pancreatic cancer	0.00027	0.00125	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Docetaxel—pancreatic cancer	0.000267	0.00123	CcSEcCtD
Fluocinolone Acetonide—Nausea—Sunitinib—pancreatic cancer	0.000267	0.00123	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000261	0.00121	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000261	0.00121	CcSEcCtD
Fluocinolone Acetonide—Oedema—Docetaxel—pancreatic cancer	0.000256	0.00118	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Gemcitabine—pancreatic cancer	0.000255	0.00118	CcSEcCtD
Fluocinolone Acetonide—Infection—Docetaxel—pancreatic cancer	0.000254	0.00117	CcSEcCtD
Fluocinolone Acetonide—Sinusitis—Epirubicin—pancreatic cancer	0.000254	0.00117	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Irinotecan—pancreatic cancer	0.000253	0.00117	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Docetaxel—pancreatic cancer	0.000251	0.00116	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Fluorouracil—pancreatic cancer	0.000251	0.00116	CcSEcCtD
Fluocinolone Acetonide—Infestation—Doxorubicin—pancreatic cancer	0.00025	0.00116	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Doxorubicin—pancreatic cancer	0.00025	0.00116	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Gemcitabine—pancreatic cancer	0.000247	0.00114	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—SRC—pancreatic cancer	0.000246	0.00422	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—BRCA2—pancreatic cancer	0.000245	0.00421	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Irinotecan—pancreatic cancer	0.000245	0.00113	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—IFNA5—pancreatic cancer	0.000244	0.00419	CbGpPWpGaD
Fluocinolone Acetonide—Rhinitis—Epirubicin—pancreatic cancer	0.000243	0.00113	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Fluorouracil—pancreatic cancer	0.000242	0.00112	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—PIK3CG—pancreatic cancer	0.00024	0.00413	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—NR5A2—pancreatic cancer	0.000239	0.00411	CbGpPWpGaD
Fluocinolone Acetonide—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000239	0.0011	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—SMAD4—pancreatic cancer	0.000237	0.00408	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—STAT3—pancreatic cancer	0.000237	0.00407	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Irinotecan—pancreatic cancer	0.000235	0.00109	CcSEcCtD
Fluocinolone Acetonide—Sinusitis—Doxorubicin—pancreatic cancer	0.000235	0.00109	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Fluorouracil—pancreatic cancer	0.000234	0.00108	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Epirubicin—pancreatic cancer	0.000234	0.00108	CcSEcCtD
Fluocinolone Acetonide—Rash—Irinotecan—pancreatic cancer	0.000233	0.00108	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TYMS—pancreatic cancer	0.000233	0.004	CbGpPWpGaD
Fluocinolone Acetonide—Dermatitis—Irinotecan—pancreatic cancer	0.000233	0.00108	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000233	0.00108	CcSEcCtD
Fluocinolone Acetonide—Headache—Irinotecan—pancreatic cancer	0.000232	0.00107	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PPP2R5B—pancreatic cancer	0.00023	0.00395	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Gemcitabine—pancreatic cancer	0.000229	0.00106	CcSEcCtD
Fluocinolone Acetonide—Rash—Gemcitabine—pancreatic cancer	0.000227	0.00105	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Gemcitabine—pancreatic cancer	0.000227	0.00105	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Epirubicin—pancreatic cancer	0.000227	0.00105	CcSEcCtD
Fluocinolone Acetonide—Headache—Gemcitabine—pancreatic cancer	0.000226	0.00104	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Fluorouracil—pancreatic cancer	0.000225	0.00104	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Doxorubicin—pancreatic cancer	0.000225	0.00104	CcSEcCtD
Fluocinolone Acetonide—Rash—Fluorouracil—pancreatic cancer	0.000223	0.00103	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Fluorouracil—pancreatic cancer	0.000223	0.00103	CcSEcCtD
Fluocinolone Acetonide—Headache—Fluorouracil—pancreatic cancer	0.000222	0.00103	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—PIK3CG—pancreatic cancer	0.000222	0.00381	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000221	0.00102	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000221	0.00102	CcSEcCtD
Fluocinolone Acetonide—Nausea—Irinotecan—pancreatic cancer	0.00022	0.00102	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CDKN2A—pancreatic cancer	0.000219	0.00377	CbGpPWpGaD
Fluocinolone Acetonide—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000219	0.00101	CcSEcCtD
Fluocinolone Acetonide—Pain—Docetaxel—pancreatic cancer	0.000219	0.00101	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Doxorubicin—pancreatic cancer	0.000217	0.001	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—EGFR—pancreatic cancer	0.000215	0.0037	CbGpPWpGaD
Fluocinolone Acetonide—Alopecia—Epirubicin—pancreatic cancer	0.000215	0.000992	CcSEcCtD
Fluocinolone Acetonide—Nausea—Gemcitabine—pancreatic cancer	0.000214	0.00099	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Epirubicin—pancreatic cancer	0.000213	0.000984	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Epirubicin—pancreatic cancer	0.000211	0.000977	CcSEcCtD
Fluocinolone Acetonide—Erythema—Epirubicin—pancreatic cancer	0.000211	0.000977	CcSEcCtD
Fluocinolone Acetonide—Nausea—Fluorouracil—pancreatic cancer	0.00021	0.000973	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Doxorubicin—pancreatic cancer	0.00021	0.000971	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of Androgen receptor activity—SRC—pancreatic cancer	0.000207	0.00356	CbGpPWpGaD
Fluocinolone Acetonide—Dysgeusia—Epirubicin—pancreatic cancer	0.000207	0.000957	CcSEcCtD
Fluocinolone Acetonide—Back pain—Epirubicin—pancreatic cancer	0.000204	0.000945	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000202	0.000936	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Docetaxel—pancreatic cancer	0.000202	0.000935	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Epirubicin—pancreatic cancer	0.000199	0.000921	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—PIK3CA—pancreatic cancer	0.000199	0.00342	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CXCL8—pancreatic cancer	0.000199	0.00342	CbGpPWpGaD
Fluocinolone Acetonide—Alopecia—Doxorubicin—pancreatic cancer	0.000199	0.000918	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Doxorubicin—pancreatic cancer	0.000197	0.00091	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Doxorubicin—pancreatic cancer	0.000196	0.000904	CcSEcCtD
Fluocinolone Acetonide—Erythema—Doxorubicin—pancreatic cancer	0.000196	0.000904	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—PIK3CD—pancreatic cancer	0.000195	0.00335	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—HES1—pancreatic cancer	0.000193	0.00331	CbGpPWpGaD
Fluocinolone Acetonide—Dysgeusia—Doxorubicin—pancreatic cancer	0.000192	0.000886	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PRLHR—pancreatic cancer	0.000191	0.00327	CbGpPWpGaD
Fluocinolone Acetonide—Vertigo—Epirubicin—pancreatic cancer	0.00019	0.000878	CcSEcCtD
Fluocinolone Acetonide—Back pain—Doxorubicin—pancreatic cancer	0.000189	0.000875	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Docetaxel—pancreatic cancer	0.000188	0.000871	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—CTNNB1—pancreatic cancer	0.000188	0.00323	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—HIF1A—pancreatic cancer	0.000187	0.00321	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CCND1—pancreatic cancer	0.000185	0.00318	CbGpPWpGaD
Fluocinolone Acetonide—Cough—Epirubicin—pancreatic cancer	0.000184	0.000853	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Doxorubicin—pancreatic cancer	0.000184	0.000852	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—pancreatic cancer	0.000184	0.00317	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—PIK3CB—pancreatic cancer	0.000184	0.00316	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CTNNB1—pancreatic cancer	0.000184	0.00315	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Docetaxel—pancreatic cancer	0.000181	0.000837	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—MMP9—pancreatic cancer	0.00018	0.00309	CbGpPWpGaD
Fluocinolone Acetonide—Arthralgia—Epirubicin—pancreatic cancer	0.00018	0.000832	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Endothelins—HRAS—pancreatic cancer	0.00018	0.00308	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—PTEN—pancreatic cancer	0.000179	0.00307	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—NFKBIA—pancreatic cancer	0.000177	0.00303	CbGpPWpGaD
Fluocinolone Acetonide—Vertigo—Doxorubicin—pancreatic cancer	0.000176	0.000813	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—pancreatic cancer	0.000175	0.00301	CbGpPWpGaD
Fluocinolone Acetonide—Diarrhoea—Docetaxel—pancreatic cancer	0.000175	0.000809	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—GDI2—pancreatic cancer	0.000175	0.003	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—GDI1—pancreatic cancer	0.000175	0.003	CbGpPWpGaD
Fluocinolone Acetonide—Oedema—Epirubicin—pancreatic cancer	0.000173	0.000798	CcSEcCtD
Fluocinolone Acetonide—Infection—Epirubicin—pancreatic cancer	0.000171	0.000793	CcSEcCtD
Fluocinolone Acetonide—Cough—Doxorubicin—pancreatic cancer	0.000171	0.000789	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—PIK3CB—pancreatic cancer	0.00017	0.00292	CbGpPWpGaD
Fluocinolone Acetonide—Nervous system disorder—Epirubicin—pancreatic cancer	0.000169	0.000782	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGF—pancreatic cancer	0.000169	0.00291	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Docetaxel—pancreatic cancer	0.000169	0.000782	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Doxorubicin—pancreatic cancer	0.000167	0.00077	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—AKT1—pancreatic cancer	0.000163	0.00279	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Docetaxel—pancreatic cancer	0.000163	0.000752	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—SSTR3—pancreatic cancer	0.000162	0.00278	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—HIF1A—pancreatic cancer	0.000162	0.00278	CbGpPWpGaD
Fluocinolone Acetonide—Rash—Docetaxel—pancreatic cancer	0.000161	0.000746	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Docetaxel—pancreatic cancer	0.000161	0.000745	CcSEcCtD
Fluocinolone Acetonide—Headache—Docetaxel—pancreatic cancer	0.00016	0.000741	CcSEcCtD
Fluocinolone Acetonide—Oedema—Doxorubicin—pancreatic cancer	0.00016	0.000738	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—PTEN—pancreatic cancer	0.000159	0.00273	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—PPARG—pancreatic cancer	0.000159	0.00273	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Endothelins—AKT1—pancreatic cancer	0.000159	0.00272	CbGpPWpGaD
Fluocinolone Acetonide—Infection—Doxorubicin—pancreatic cancer	0.000159	0.000733	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000157	0.000727	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000157	0.000724	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—SSTR1—pancreatic cancer	0.000155	0.00267	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—AKT1—pancreatic cancer	0.000153	0.00262	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PPY—pancreatic cancer	0.000152	0.00262	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CG—pancreatic cancer	0.000152	0.00262	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—RB1—pancreatic cancer	0.000152	0.00261	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Docetaxel—pancreatic cancer	0.000152	0.000703	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—TGFB1—pancreatic cancer	0.000152	0.00261	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—EGF—pancreatic cancer	0.000151	0.00259	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—SSTR2—pancreatic cancer	0.00015	0.00257	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—pancreatic cancer	0.00015	0.00257	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000149	0.000689	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—MYC—pancreatic cancer	0.000149	0.00255	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—TGFB1—pancreatic cancer	0.000148	0.00255	CbGpPWpGaD
Fluocinolone Acetonide—Pain—Epirubicin—pancreatic cancer	0.000148	0.000682	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—SRC—pancreatic cancer	0.000147	0.00253	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—PTEN—pancreatic cancer	0.000147	0.00252	CbGpPWpGaD
Fluocinolone Acetonide—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000145	0.000672	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CCKBR—pancreatic cancer	0.000144	0.00248	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—STAT3—pancreatic cancer	0.000142	0.00244	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—NRAS—pancreatic cancer	0.000142	0.00244	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—CD44—pancreatic cancer	0.000138	0.00237	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000138	0.000637	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Gene Expression—CHD3—pancreatic cancer	0.000137	0.00236	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—MEN1—pancreatic cancer	0.000137	0.00236	CbGpPWpGaD
Fluocinolone Acetonide—Pain—Doxorubicin—pancreatic cancer	0.000136	0.000631	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Epirubicin—pancreatic cancer	0.000136	0.000631	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CD—pancreatic cancer	0.000134	0.0023	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—IFNA1—pancreatic cancer	0.000134	0.00229	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—pancreatic cancer	0.000132	0.00227	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—MYC—pancreatic cancer	0.000132	0.00227	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—NOTCH4—pancreatic cancer	0.00013	0.00224	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—pancreatic cancer	0.00013	0.00223	CbGpPWpGaD
Fluocinolone Acetonide—Hypersensitivity—Epirubicin—pancreatic cancer	0.000127	0.000588	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PRSS1—pancreatic cancer	0.000127	0.00217	CbGpPWpGaD
Fluocinolone Acetonide—Body temperature increased—Doxorubicin—pancreatic cancer	0.000126	0.000583	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—IFNA2—pancreatic cancer	0.000124	0.00214	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—GAST—pancreatic cancer	0.000124	0.00213	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—TP53—pancreatic cancer	0.000122	0.0021	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—KRAS—pancreatic cancer	0.000122	0.0021	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Epirubicin—pancreatic cancer	0.000122	0.000564	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	0.000121	0.00207	CbGpPWpGaD
Fluocinolone Acetonide—Diarrhoea—Epirubicin—pancreatic cancer	0.000118	0.000546	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—SCT—pancreatic cancer	0.000118	0.00202	CbGpPWpGaD
Fluocinolone Acetonide—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000118	0.000544	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	0.000117	0.00202	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CB—pancreatic cancer	0.000117	0.002	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	0.000116	0.002	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—NR5A2—pancreatic cancer	0.000115	0.00198	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Epirubicin—pancreatic cancer	0.000114	0.000528	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	0.000113	0.00195	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Doxorubicin—pancreatic cancer	0.000113	0.000522	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PRLHR—pancreatic cancer	0.000113	0.00193	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CCK—pancreatic cancer	0.000112	0.00193	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—PIK3CA—pancreatic cancer	0.000112	0.00193	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—CTNNB1—pancreatic cancer	0.000112	0.00192	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—NOTCH3—pancreatic cancer	0.000111	0.0019	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ARG2—pancreatic cancer	0.00011	0.00189	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Epirubicin—pancreatic cancer	0.00011	0.000507	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CNR2—pancreatic cancer	0.000109	0.00188	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—GLP1R—pancreatic cancer	0.000109	0.00188	CbGpPWpGaD
Fluocinolone Acetonide—Diarrhoea—Doxorubicin—pancreatic cancer	0.000109	0.000505	CcSEcCtD
Fluocinolone Acetonide—Rash—Epirubicin—pancreatic cancer	0.000109	0.000503	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Epirubicin—pancreatic cancer	0.000109	0.000503	CcSEcCtD
Fluocinolone Acetonide—Headache—Epirubicin—pancreatic cancer	0.000108	0.0005	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CCKAR—pancreatic cancer	0.000108	0.00185	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—pancreatic cancer	0.000108	0.00185	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—ACVR1B—pancreatic cancer	0.000106	0.00182	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—ZNRF3—pancreatic cancer	0.000106	0.00182	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Doxorubicin—pancreatic cancer	0.000106	0.000488	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	0.000105	0.0018	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—CXCL8—pancreatic cancer	0.000105	0.0018	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—HRAS—pancreatic cancer	0.000104	0.00178	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—PIK3CA—pancreatic cancer	0.000104	0.00178	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Epirubicin—pancreatic cancer	0.000102	0.000474	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	0.000102	0.00176	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Doxorubicin—pancreatic cancer	0.000101	0.000469	CcSEcCtD
Fluocinolone Acetonide—Rash—Doxorubicin—pancreatic cancer	0.000101	0.000465	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Doxorubicin—pancreatic cancer	0.000101	0.000465	CcSEcCtD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—CASP3—pancreatic cancer	0.0001	0.00172	CbGpPWpGaD
Fluocinolone Acetonide—Headache—Doxorubicin—pancreatic cancer	0.0001	0.000462	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—SHH—pancreatic cancer	9.82e-05	0.00169	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—STAT3—pancreatic cancer	9.75e-05	0.00168	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—IAPP—pancreatic cancer	9.7e-05	0.00167	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—CTNNB1—pancreatic cancer	9.67e-05	0.00166	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—TYMP—pancreatic cancer	9.59e-05	0.00165	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—DTX1—pancreatic cancer	9.57e-05	0.00164	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SSTR3—pancreatic cancer	9.57e-05	0.00164	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Doxorubicin—pancreatic cancer	9.48e-05	0.000438	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	9.42e-05	0.00162	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	9.39e-05	0.00161	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—SRC—pancreatic cancer	9.35e-05	0.00161	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PTHLH—pancreatic cancer	9.31e-05	0.0016	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PTCH1—pancreatic cancer	9.31e-05	0.0016	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	9.21e-05	0.00158	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SSTR1—pancreatic cancer	9.18e-05	0.00158	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—pancreatic cancer	9.18e-05	0.00158	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—pancreatic cancer	9.11e-05	0.00156	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—AKT1—pancreatic cancer	9.09e-05	0.00156	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—TGFB1—pancreatic cancer	9.04e-05	0.00155	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PPY—pancreatic cancer	9e-05	0.00155	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SSTR2—pancreatic cancer	8.84e-05	0.00152	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PLAU—pancreatic cancer	8.82e-05	0.00152	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	8.77e-05	0.00151	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	8.7e-05	0.00149	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CCKBR—pancreatic cancer	8.53e-05	0.00147	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—VEGFA—pancreatic cancer	8.51e-05	0.00146	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—SST—pancreatic cancer	8.51e-05	0.00146	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—TNF—pancreatic cancer	8.44e-05	0.00145	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—TGFB1—pancreatic cancer	8.36e-05	0.00144	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—SMAD4—pancreatic cancer	8.34e-05	0.00143	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—DTX4—pancreatic cancer	8.02e-05	0.00138	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—GLI1—pancreatic cancer	8.02e-05	0.00138	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	7.99e-05	0.00137	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	7.92e-05	0.00136	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CNR1—pancreatic cancer	7.86e-05	0.00135	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PIK3CG—pancreatic cancer	7.85e-05	0.00135	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—NRP1—pancreatic cancer	7.8e-05	0.00134	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PPP2R5B—pancreatic cancer	7.8e-05	0.00134	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—EGF—pancreatic cancer	7.76e-05	0.00133	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GLP1R—pancreatic cancer	7.73e-05	0.00133	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	7.73e-05	0.00133	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—DPYD—pancreatic cancer	7.61e-05	0.00131	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—GCG—pancreatic cancer	7.59e-05	0.0013	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—HEY2—pancreatic cancer	7.51e-05	0.00129	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—GAST—pancreatic cancer	7.34e-05	0.00126	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—TNF—pancreatic cancer	7.3e-05	0.00125	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—AGTR1—pancreatic cancer	7.24e-05	0.00124	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—SLC2A2—pancreatic cancer	7.22e-05	0.00124	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	7.15e-05	0.00123	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CA—pancreatic cancer	7.11e-05	0.00122	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SCT—pancreatic cancer	6.96e-05	0.00119	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—HEY1—pancreatic cancer	6.96e-05	0.00119	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PIK3CD—pancreatic cancer	6.9e-05	0.00119	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	6.9e-05	0.00118	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CCK—pancreatic cancer	6.64e-05	0.00114	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—MEN1—pancreatic cancer	6.62e-05	0.00114	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	6.53e-05	0.00112	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CNR2—pancreatic cancer	6.47e-05	0.00111	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—GLP1R—pancreatic cancer	6.47e-05	0.00111	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CCKAR—pancreatic cancer	6.36e-05	0.00109	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	6.28e-05	0.00108	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—NOTCH4—pancreatic cancer	6.27e-05	0.00108	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—JAG2—pancreatic cancer	6.17e-05	0.00106	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—NOTCH1—pancreatic cancer	6.15e-05	0.00106	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MEN1—pancreatic cancer	6.08e-05	0.00104	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PIK3CB—pancreatic cancer	6.01e-05	0.00103	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—HSPA1B—pancreatic cancer	5.98e-05	0.00103	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	5.81e-05	0.000998	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—PPARG—pancreatic cancer	5.8e-05	0.000997	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SHH—pancreatic cancer	5.8e-05	0.000996	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—NOTCH4—pancreatic cancer	5.76e-05	0.00099	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IAPP—pancreatic cancer	5.73e-05	0.000984	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CD44—pancreatic cancer	5.59e-05	0.00096	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PTHLH—pancreatic cancer	5.5e-05	0.000944	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PTCH1—pancreatic cancer	5.5e-05	0.000944	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	5.48e-05	0.00094	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—EZH2—pancreatic cancer	5.45e-05	0.000936	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	5.43e-05	0.000932	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GCG—pancreatic cancer	5.36e-05	0.000921	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—NOTCH3—pancreatic cancer	5.33e-05	0.000916	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—HSPA1A—pancreatic cancer	5.05e-05	0.000868	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—STK11—pancreatic cancer	5.04e-05	0.000866	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SST—pancreatic cancer	5.03e-05	0.000864	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—JAG1—pancreatic cancer	4.92e-05	0.000845	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—NOTCH3—pancreatic cancer	4.9e-05	0.000842	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—SRC—pancreatic cancer	4.82e-05	0.000828	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	4.73e-05	0.000813	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—VEGFA—pancreatic cancer	4.69e-05	0.000806	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CNR1—pancreatic cancer	4.64e-05	0.000797	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—NRAS—pancreatic cancer	4.64e-05	0.000796	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PIK3CG—pancreatic cancer	4.5e-05	0.000774	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—GCG—pancreatic cancer	4.48e-05	0.00077	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—TYMS—pancreatic cancer	4.34e-05	0.000745	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—TGFB1—pancreatic cancer	4.31e-05	0.00074	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—AGTR1—pancreatic cancer	4.28e-05	0.000734	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—STK11—pancreatic cancer	4.21e-05	0.000724	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—SMAD4—pancreatic cancer	4.02e-05	0.00069	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—KRAS—pancreatic cancer	3.99e-05	0.000685	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PIK3CD—pancreatic cancer	3.96e-05	0.00068	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SMAD4—pancreatic cancer	3.69e-05	0.000634	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PIK3CA—pancreatic cancer	3.67e-05	0.00063	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—HES1—pancreatic cancer	3.6e-05	0.000619	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—TP53—pancreatic cancer	3.55e-05	0.000609	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—APOE—pancreatic cancer	3.53e-05	0.000606	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PIK3CB—pancreatic cancer	3.45e-05	0.000593	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—HRAS—pancreatic cancer	3.39e-05	0.000583	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.34e-05	0.000573	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CXCL8—pancreatic cancer	3.32e-05	0.00057	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—MYC—pancreatic cancer	3.31e-05	0.000568	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PIK3CG—pancreatic cancer	3.18e-05	0.000547	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TERT—pancreatic cancer	3.16e-05	0.000542	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PPARG—pancreatic cancer	3.07e-05	0.000528	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—HIF1A—pancreatic cancer	3.02e-05	0.000519	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TSC2—pancreatic cancer	3.01e-05	0.000517	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—AKT1—pancreatic cancer	2.99e-05	0.000514	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—NOTCH1—pancreatic cancer	2.96e-05	0.000509	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—APOE—pancreatic cancer	2.95e-05	0.000506	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—KDR—pancreatic cancer	2.89e-05	0.000496	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PIK3CD—pancreatic cancer	2.8e-05	0.000481	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—PPARG—pancreatic cancer	2.79e-05	0.00048	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—NFKBIA—pancreatic cancer	2.75e-05	0.000472	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—NOTCH1—pancreatic cancer	2.72e-05	0.000467	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PIK3CG—pancreatic cancer	2.66e-05	0.000457	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—NRAS—pancreatic cancer	2.66e-05	0.000457	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—EGF—pancreatic cancer	2.63e-05	0.000452	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PIK3CB—pancreatic cancer	2.44e-05	0.000419	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—EGFR—pancreatic cancer	2.42e-05	0.000416	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PTGS2—pancreatic cancer	2.42e-05	0.000415	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PIK3CD—pancreatic cancer	2.34e-05	0.000402	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—KRAS—pancreatic cancer	2.29e-05	0.000393	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PTEN—pancreatic cancer	2.11e-05	0.000362	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PIK3CA—pancreatic cancer	2.1e-05	0.000361	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PIK3CB—pancreatic cancer	2.04e-05	0.00035	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CXCL8—pancreatic cancer	1.96e-05	0.000337	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—HRAS—pancreatic cancer	1.95e-05	0.000334	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CASP3—pancreatic cancer	1.88e-05	0.000322	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CCND1—pancreatic cancer	1.83e-05	0.000314	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CTNNB1—pancreatic cancer	1.81e-05	0.00031	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MMP9—pancreatic cancer	1.77e-05	0.000304	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PTEN—pancreatic cancer	1.76e-05	0.000303	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—AKT1—pancreatic cancer	1.72e-05	0.000295	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SRC—pancreatic cancer	1.63e-05	0.000281	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—MYC—pancreatic cancer	1.59e-05	0.000274	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—VEGFA—pancreatic cancer	1.59e-05	0.000273	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—STAT3—pancreatic cancer	1.58e-05	0.000271	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—NRAS—pancreatic cancer	1.57e-05	0.00027	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PIK3CA—pancreatic cancer	1.49e-05	0.000255	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MYC—pancreatic cancer	1.46e-05	0.000251	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TGFB1—pancreatic cancer	1.46e-05	0.000251	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—EGFR—pancreatic cancer	1.43e-05	0.000246	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—KRAS—pancreatic cancer	1.35e-05	0.000232	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PIK3CA—pancreatic cancer	1.24e-05	0.000213	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—AKT1—pancreatic cancer	1.21e-05	0.000209	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TP53—pancreatic cancer	1.2e-05	0.000207	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—HRAS—pancreatic cancer	1.15e-05	0.000198	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—AKT1—pancreatic cancer	1.1e-05	0.00019	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—AKT1—pancreatic cancer	1.02e-05	0.000174	CbGpPWpGaD
